[EN] TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION<br/>[FR] INHIBITEURS TRICYCLIQUES D'ACTIVATION DE MÉTALLOPROTÉINASES PROMATRICIELLES
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2012068211A1
公开(公告)日:2012-05-24
This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
[EN] QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS<br/>[FR] DÉRIVÉS DE QUINAZOLINE EN TANT QU'AGENTS ANTITUMORAUX
申请人:SUZHOU ZANRONG PHARMA LTD
公开号:WO2020057511A1
公开(公告)日:2020-03-26
The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.
TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
申请人:WANG Aihua
公开号:US20120129811A1
公开(公告)日:2012-05-24
This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C
1
, C
2
, Z
1
, Z
2
, Q, J, R
1
, and R
3
are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.